# FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

# Oncologic Drugs Advisory Committee (ODAC) Meeting October 5, 2023

## MEETING ROSTER

# **ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

# Joyce Frimpong, PharmD

Division of Advisory Committee and Consultant Management Office of Executive Programs, CDER, FDA

# ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

## Mark R. Conaway, PhD

Professor

Division of Translational Research and Applied Statistics

Department of Public Health Sciences

The University of Virginia School of Medicine

Charlottesville, Virginia

## Ravi A. Madan, MD

(Chairperson)

Senior Clinician

Head, Prostate Cancer Clinical Research Section

Genitourinary Malignancies Branch

Center for Cancer Research (CRC)

National Cancer Institute (NCI)

National Institutes of Health (NIH)

Bethesda, Maryland

## Jorge J. Nieva, MD

Associate Professor of Clinical Medicine

Section Head, Solid Tumors

University of Southern California (USC) Norris

Comprehensive Cancer Center

Keck School of Medicine of USC

Los Angeles, California

## **Daniel Spratt, MD**

Vincent K Smith Chair, Department of Radiation

Oncology

Professor of Radiation Oncology and Urology

University Hospitals Seidman Cancer Center

Case Western Reserve University

Cleveland, Ohio

## William J. Gradishar, MD

Professor of Medicine/Betsy Bramsen Professor of

**Breast Oncology** 

Chief, Hematology/Oncology

Robert H. Lurie Comprehensive Cancer Center

Feinberg School of Medicine at Northwestern

University

Chicago, Illinois

## **David E. Mitchell**

(Consumer Representative)

President

Patients for Affordable Drugs

Bethesda, Maryland

#### Ashley Rosko, MD

Associate Professor

Division of Hematology

Medical Director Oncogeriatric

The Ohio State University Comprehensive Cancer

Center

Columbus, Ohio

#### Neil Vasan, MD, PhD

**Assistant Professor** 

Division of Hematology & Oncology

Department of Medicine

Herbert Irving Comprehensive Cancer Center

Columbia University Medical Center

New York, New York

# FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

# Oncologic Drugs Advisory Committee (ODAC) Meeting October 5, 2023

# **MEETING ROSTER (cont.)**

## ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

## Albert L. Kraus, PhD

(Acting Industry Representative)
Managing Partner
GDS Partners, LLC
Guilford, Connecticut

# **TEMPORARY MEMBERS (Voting)**

# James L. Gulley, MD, PhD, FACP

Medical Oncology Co-Director Center for Immuno-Oncology, CRC, NCI Clinical Director, NCI, NIH Bethesda, Maryland

## **James Pantelas**

(Patient Representative) Howell, Michigan

# Philip C. Hoffman, MD

Clinical Professor of Medicine Section of Hematology/Oncology University of Chicago Chicago, Illinois

# Pamela Shaw, PhD, MS

Senior Investigator Biostatistics Division Kaiser Permanente Washington Health Research Institute Seattle, Washington

# FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

# Oncologic Drugs Advisory Committee (ODAC) Meeting October 5, 2023

# **MEETING ROSTER (cont.)**

# FDA PARTICIPANTS (Non-Voting)

#### Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE) Office of the Commissioner (OC) Director (Acting) Office of Oncologic Diseases (OOD) Office of New Drugs (OND), CDER, FDA

## Paz Vellanki, MD, PhD

Cross Disciplinary Team Lead DO2, OOD, OND, CDER, FDA

## Pallavi Mishra-Kalyani, PhD

Deputy Director Division of Biometrics V (DBV) Office of Biostatistics (OB) Office of Translation Sciences (OTS) CDER, FDA

# Chi (Chuck) Song, PhD

Statistical Reviewer DBV, OB, OTS, CDER, FDA

# Harpreet Singh, MD

Director
Division of Oncology 2 (DO2)
OOD, OND, CDER, FDA

## Jeevan Puthiamadathil, MD

Clinical Reviewer DO2, OOD, OND, CDER, FDA

#### Anup Amatya, PhD

Biometrics Team Leader DBV, OB, OTS, CDER, FDA